Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib

Molecular Cancer Therapeutics

Volumn 8, Issue 6, 2009, Pages 1438-1447

  Wang, Shining ^a,b   Zhou, Qingyu ^a   Gallo, James M ^a  

^a TEMPLE UNIVERSITY   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; WILD TYPE;

ALGORITHMS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOBLASTOMA; HUMANS; MALE; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTATION; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; THERAPEUTIC EQUIVALENCY; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67649344800     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0089     Document Type: Article

References (20)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
2. Dutta PR, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett 2007;254:165-177 (Pubitemid 47161103)
3. Halatsch M-E, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumors. Cancer Treat Rev 2006;32:74-89. (Pubitemid 43362229)
4. Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiform patients. Clin Cancer Res 2005;15:1462-1466 (Pubitemid 40315227)
5. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-2024 (Pubitemid 41609094)
6. Schilsky RL, Gordon G, Gilmer TM, et al. The translational research working group developmental pathway for anticancer agents (drugs or biologics). Clin Cancer Res 2008;14:5685-5691
7. Woodcock J, Woosley R. The FDA ciritical path initiative and its influence on new drug development. Annu Rev Med 2008;59:1-12. (Pubitemid 351287920)
8. Zhou Q, Guo P, Kruh GD, Vicini P, Wang X, Gallo JM. Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. Clin Cancer Res 2007;13:4271-4279
9. Wang S, Guo P, Wang X, Zhou S, Gallo JM. Preclinical pharmacokinetic/ pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Mol Cancer Ther 2008;7:407-417 (Pubitemid 351302534)
10. Hofer S, Frei K, Rutz HP. Gefitinib accumulation in glioblastoma tissue. Cancer Biol Ther 2006;5:483-484 (Pubitemid 43765281)
11. Barrett PH, Bell BM, Cobelli C, et al. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism 1998;47:484-492 (Pubitemid 28180958)
12. Norton L. A Gompertz model of human breast cancer growth. Cancer Res 1988;48:7067-7071 (Pubitemid 19013983)
13. Bueno L, de Alwis DP, Pitou C, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice. Eur J Cancer 2008;44:142-150 (Pubitemid 350256941)
14. Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003;14:922-930 (Pubitemid 36827209)
15. Swaisland HC, Smith RP, Laight A, et al. Single-dose clinical pharmacokinetics studies of gefitinib. Clin Pharmacokinet 2005;44:1165-1177 (Pubitemid 41483701)
16. Reardon DA, Quinn JA, Vredenburgh JJ, et al. Phase I trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 2006;12:860-868 (Pubitemid 43259869)
17. Pardos MD, Yung WK, Wen PY, et al. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol 2008;61:1059-1067
18. Lassman AB, Rossi MR, Raizer JJ, et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brian Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005;11:7841-7850 (Pubitemid 41611629)
19. Li J, Cusatis G, Brahmer J, et al. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Caner Biol Ther 2007;6:432-438 (Pubitemid 47328313)
20. Levin VA. Pharmacokinetics and CNS chemotherapy. In: Hellmann K, Carter SK, editors. Fundamentals of cancer chemotherapy. New York: McGraw-Hill; 1986. p. 28.